Lymph node mapping in gastric cancer: a pilot study in Western patients

Article Figures & Tables

Download figure
Open in new tab
Download powerpoint
Fig. 1
Detecting indocyanine green fluorescence with laparoscopic fluorescence imaging camera.
Download figure
Open in new tab
Download powerpoint
Fig. 2
Detection of a basin 9 lymph node.
Download figure
Open in new tab
Download powerpoint
Fig. 3
Mapping of the proximal margin of the primary tumour.

Table 1

Baseline patient characteristics

ICG = Indocyanine green fluorescence; IQR = interquartile range; LN = lymph nodes.
↵* Unless indicated otherwise.

Table 2

Perioperative clinical management and outcomes

Patient	cT stage	Neoadjuvant	Margins	pTN stage	Postoperative chemo	Complications
1	2	FLOT	neg	ypT2N3a	FLOT	No

2	1	No	neg	pT2N0	CAPOX	No

3	3	FLOT	neg	ypT2N0	FLOT	PF

4	1	No	neg	pT2N0	No	PF

5	1	No	neg	pT2N0	No	No

6	3	No	neg	pT4aN3a	No	No

7	3	FOLFOX	neg	ypT3N1	FOLFOX	No

8	2	No	neg	pT2N2	No	No
9	1	No	pos	pT3N0	CAPOX	GIB
10	3	No	neg	pT2N0	No	NSTEMI

11	2	No	neg	pT1bN0	No	No

12	3	FLOT	neg	ypT3N0	FLOT	No

13	3	FLOT	neg	ypT1bN0	FLOT	No

CAPOX = capecitabine, oxaliplatin; FLOT = 5-fluorouracil, leucovorin, oxaliplatin, docetaxel; FOLFOX = 5-fluorouracil, leucovorin, oxaliplatin; GIB = gastrointestinal bleed; NSTEMI = non-ST-elevation myocardial infarction; PF = pancreatic fistula.

Table 3

Patient-specific nodal mapping

Patient	No. of LNs	ICG D1^* basins	ICG D1+^†/D2^‡ basins	Positive D1 LN	Positive D1+/D2 LN
1	26	1, 3, 4, 5, 6	8, 12a	Yes	No
2	35	1, 3, 4, 5	9, 12a	No	No
3	18	1, 3, 5, 6, 7	9, 11p, 12a	No	No
4	33	1, 3, 4, 5, 7	9, 11p	No	No
5	24	3, 7	9, 11p	No	No
6	25	3, 4, 6, 7	9, 11p	Yes	No
7	30	3, 4, 5, 6	8	Yes	No
8	23	3, 4, 5, 6, 7	8, 9	Yes	Yes (12-a 1/1)
9	21	5, 6	8	No	No
10	31	3, 4, 6	8, 9	No	No
11	43	3, 5, 7	8	No	No
12	24	1, 3, 4, 5, 6, 7	8, 9, 11p	No	No
13	38	1, 3, 5, 6	8	No	No